Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Before vs After PRP for DME in PDR
NCT00804206Phase 4Terminated
- Sponsor
- Asociación para Evitar la Ceguera en México
- Start
- Jul 2008
- Primary completion
- Jul 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bevacizumab in diabetic macular edema (DME), sponsored by Asociación para Evitar la Ceguera en México. Primary endpoint: Central Macular Thickness at 85 days. Started Jul 2008; status: terminated.
02
Drugs
bevacizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT00804206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00804206.